BARD1 Presenting at Bell Potter Healthcare Conference

For personal use only

Detecting cancer earlier to save lives

Bell Potter Healthcare Conference 10 November 2021

Leearne Hinch | CEO

For personal use only

Disclaimer

This presentation has been prepared by BARD1 Life Sciences Limited ("BARD1" or the "Company") based on information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and performance, profits and losses, prospects, and the rights and liabilities attaching to the Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), available at www.asx.com.au. The information in this presentation is based on the Company's own information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward- looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including BARD1 or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of BARD1 cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

only

Company overview

BARD1 Life Sciences (ASX: BD1)

BARD1 History

2016 BARD1 AAb technology acquired

2020 SubB2M and EXO-NET® technologies acquired / in-licensed

use

2021

SubB2M proof-of-concept results for breast and ovarian cancers

RUO EXO-NET exosome capture tool launched

For personal

Board and management

Share price performance (Past 12 months)

For personal use only

Global cancer diagnostics market

• Global cancer burden: 50.6m people, 19.3m new cases and 10.0m deaths p.a.1
• Global cancer diagnostics market valued at US$250b2
• BARD1 is targeting markets worth US$11b for some of the world's most common and deadliest cancers

US$2.4b